Overview

Comparative Bioavailability of Risperidone

Status:
Completed

Trial end date:
2019-04-06

Target enrollment:

Participant gender:

Summary

This is an open-label, one sequence study to evaluate the steady-state comparative bioavailability of 100 mg Risperidone ISM® injectable every 4 weeks compared to once daily 4 mg oral risperidone in subjects with schizophrenia stabilized on oral risperidone treatment.

Phase:

Phase 1

Details

Lead Sponsor:

Rovi Pharmaceuticals Laboratories

Treatments:

Risperidone